Sponsors (7)
The bill speeds deployment and local access to apheresis collection devices and reduces some administrative costs, but it increases the chance of site-level safety lapses and reduces FDA's ability to intervene, trading faster access and lower costs for greater regulatory and safety risk.
Patients who need apheresis therapies (e.g., chronic-condition patients) could get faster local access because blood centers can add approved apheresis devices more quickly.
Hospitals, blood centers, and donors could see expanded service availability and greater convenience because multi-site licensed or accredited centers can expand services more quickly, potentially increasing supply.
Hospitals, blood centers, and device operators could face lower administrative costs and faster deployment of collection devices due to shorter FDA review timelines for routine supplemental BLAs.
Patients who receive apheresis therapies and hospitals could face higher safety risks if the 30-day automatic approval window is too short to detect site-specific problems.
Patients and health systems could experience uneven regulatory oversight and reduced federal scrutiny if the FDA's ability to delay approvals is limited, risking product quality across locations.
Taxpayers and patients could bear additional costs if expedited expansion leads to recalls or corrective actions that require publicly funded responses.
Based on analysis of 2 sections of legislative text.
Requires HHS to create an expedited FDA review so qualifying blood center operators can add apheresis collection devices at new locations with approval within 30 days unless safety issues exist.
Introduced October 17, 2025 by Tony Wied · Last progress October 17, 2025
Requires the Secretary of Health and Human Services to set up, within 180 days, a fast-track FDA approval process for supplemental biologics license applications that add an apheresis collection device at a blood center location not previously licensed for such a device. Under the expedited process, the Secretary must approve qualifying supplemental applications within 30 days unless there is a specific safety/purity/potency concern at that location or a demonstrated, systemic failure by the owner/operator at other licensed sites.